Print Page     Close Window     

SEC Filings

8-K
SERES THERAPEUTICS, INC. filed this Form 8-K on 11/08/2018
Entire Document
 


SERES THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited, in thousands, except share and per share data)

 

     September 30
2018
    December 31,
2017
 

Assets

    

Current assets:

    

Cash and cash equivalents

   $ 55,713     $ 36,088  

Investments

     17,177       113,895  

Prepaid expenses and other current assets

     6,556       5,095  
  

 

 

   

 

 

 

Total current assets

     79,446       155,078  

Property and equipment, net

     28,083       32,931  

Restricted cash

     1,513       1,513  
  

 

 

   

 

 

 

Total assets

   $ 109,042     $ 189,522  
  

 

 

   

 

 

 

Liabilities and Stockholders’ Equity/(Deficit)

    

Current liabilities:

    

Accounts payable

   $ 6,475     $ 7,033  

Accrued expenses and other current liabilities

     14,634       12,513  

Deferred revenue - related party

     17,901       12,079  
  

 

 

   

 

 

 

Total current liabilities

     39,010       31,625  

Lease incentive obligation, net of current portion

     7,685       8,989  

Deferred rent

     2,229       2,233  

Deferred revenue, net of current portion–related party

     89,554       84,847  

Other long-term liabilities

     1,129       1,129  
  

 

 

   

 

 

 

Total liabilities

     139,607       128,823  
  

 

 

   

 

 

 

Commitments and contingencies

    

Stockholders’ equity/(deficit):

    

Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2018 and December 31, 2017; no shares issued and outstanding at September 30, 2018 and December 31, 2017

     —         —    

Common stock, $0.001 par value; 200,000,000 shares authorized at September 30, 2018 and December 31, 2017; 40,844,455 and 40,571,015 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively

     41       40  

Additional paid-in capital

     337,486       324,376  

Accumulated other comprehensive loss

     (9     (146

Accumulated deficit

     (368,083     (263,571
  

 

 

   

 

 

 

Total stockholders’ equity/(deficit)

     (30,565     60,699  
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 109,042     $ 189,522  
  

 

 

   

 

 

 

© Seres Therapeutics. All Rights Reserved.